期刊文献+

新型CpG ODN对乙型肝炎病毒复制的抑制作用 被引量:2

In vitro study on the inhibitory effects of a novel CpG ODN on HBV replication
下载PDF
导出
摘要 目的:探讨我室自行设计的CpG ODN(CpG BW001)在体外对乙型肝炎病毒(HBV)复制的抑制作用。方法:CpGBW001刺激人外周血单个核细胞(PBMC)48小时,用VSV病毒保护实验及ELISA法检测培养上清的病毒保护能力及其中的IFNα-含量。将上述CpG BW001刺激人PBMC的上清与HepG2.2.15细胞共孵育12天后收集培养上清,用放射免疫法检测该培养上清液中HBsAg及HBeAg的含量,用点杂交法检测HBV DNA的含量。结果:CpG BW001刺激人PBMC产生以IFNα-为主的抗病毒物质;CpG BW001刺激人PBMC的培养上清作用于HepG2.2.15细胞后,HepG2.2.15细胞培养上清中HBsAg和HBeAg的含量明显减少,且细胞内HBV DNA的含量也显著降低。结论:CpG BW001能通过刺激细胞产生抗病毒物质如IFNα-等,从而在体外抑制HBsAg和HBeAg的表达及HBV的复制。 Objective: To study the inhibitory effect of a novel CpG ODN (CpG BW001 ) on HBV replication in vitro. Methods: The anti-viral activity in the culture supernatant of CpG BW001-treated human PBMCs was detected by VSV protection bioassay and ELISA. HepG2.2.15 ceils were cultured with these supernatants and the supematants were harvested after incubation for 12 days. The levels of HBsAg and HBeAg in the supernatants were detected by radioimmunoassay and the level of HBV DNA in HepG2.2.15 cells was examined by dot blot. Results: CpG BW001 could stimulate human PBMC to product IFN-α and protect Vero cells from VSV attack. The levels of HBsAg and HBeAg produced by HepG2.2.15 cells and the level of HBV DNA in the supernatant of HepG2.2.15 cells were declined significantly when the HepG2.2.15 cells were cultured with the supernatant of human PBMC stimulated by CpG BW001. Conclusion: The novel CpG ODN (CpG BW001 ) is identified to inhibit the expression of HBsAg, HBeAg and to block the replication of HBV in vitro.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2009年第6期487-490,共4页 Chinese Journal of Immunology
基金 国家自然科学基金海外杰出青年基金(30328010)资助项目
关键词 CPG ODN 乙型肝炎病毒 人外周血单个核细胞 干扰素 CpG ODN Hepatitis B virus Human PBMC Interferon
  • 相关文献

参考文献2

二级参考文献30

  • 1徐志强,张鸿飞,杨晓晋,杨斌,王福生.小儿慢性乙型肝炎外周血T细胞亚群和临床病理关系的研究[J].中华实验和临床病毒学杂志,2004,18(2):142-144. 被引量:15
  • 2刘源,韩亚萍,李军,黄祖瑚.慢性乙型肝炎患者外周血淋巴细胞亚群的测定分析[J].南通医学院学报,2004,24(2):140-141. 被引量:14
  • 3Liaw Y F, Leung N, Guan R, et al. Asian- Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 2003,18(3): 239-245.
  • 4Fung S K, Lok A S. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection. Hepatology, 2004,40 (4): 790-792.
  • 5Janssen H L A, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet,2005,365(9454): 123-129.
  • 6Santantonio T, Mazola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol,2000,32(2): 300-306.
  • 7Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology,2000,31(1): 207-210.
  • 8Liaw YF, Sung JJY, Chow WE, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med,2004,351 (12):1521-1531.
  • 9Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis,2003,36(6): 687-696.
  • 10Liaw YF, Chien RN, Ye CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology,1999,30(2): 567-572.

共引文献123

同被引文献15

  • 1丛中一,包木胜,万敏,王莉,李大鹏,王丽颖,于永利.新型CpG ODN增强乙肝疫苗诱导IgG2a类抗体产生的实验研究[J].中国免疫学杂志,2006,22(11):987-990. 被引量:4
  • 2CHEN J,XU W,ZHOU T,et al. Inhibitory role of tolllike receptors agonists in Plasmodium yoelii liver stage development [J]. Parasite Immunol, 2009,31 (8) : 466-473.
  • 3BERTIN S,ANJUERE F,GAVELLI A,et al. Plasmidic CpG sequences induce tumor microenvironment modifications in a rat liver metastasis model [J]. Int J Mol Med, 2008,21 ( 3 ) : 309-315.
  • 4SHARMA S,DOMINGGUEZ AL,MANRIQUE SZ,et al. Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice[J]. Cancer Res,2008,68(18): 7530-7540.
  • 5KAWABATA T,KINOSHITA M,INATSU A,et al. Functional alterations of liver innate immunity of mice with aging in response to CpG-oligodeoxynucleotide[J]. Hepatology,2008,48(5) : 1586-1597.
  • 6VAN DER BIJ GJ,OOSTERLING SJ,MEIJER S,et al. Therapeutic potential of Kupffer cells in prevention of liver metastases outgrowth[J]. Immunobiology,2005,210 (2-4) : 259-265.
  • 7OHATA K,ICHIKAWA T,NAKAO K,et al. Interferon alpha inhibits the nuclear factor kappa B activation triggered by X gene product of hepatitis B virus in human hepatoma cells[J]. FEBS Lett,2003,553(3):304-308.
  • 8王郁杰.pCMV-tag2B-HBX质粒的构建和表达[J].内科,2008,3(3):326-328. 被引量:2
  • 9董宁,姚咏明.Toll样受体免疫学研究新进展[J].感染.炎症.修复,2008,9(3):177-180. 被引量:7
  • 10韩堃,郑源强,韩新荣,石艳春.两种CpG寡核苷酸对乙型肝炎疫苗免疫小鼠淋巴细胞增殖的影响[J].中国生物制品学杂志,2008,21(11):948-950. 被引量:4

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部